Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03665922
Recruitment Status : Recruiting
First Posted : September 11, 2018
Last Update Posted : May 24, 2019
Sponsor:
Information provided by (Responsible Party):
Bruce Jacobs, University of Pittsburgh

Brief Summary:
This study will test whether oral intake of a dietary supplement called BroccoMax®, which is a special blend of broccoli extract containing a chemical called sulforaphane (hereafter abbreviated as SFN), may result in changes in chemicals that feed prostate cancer. BroccoMax® is available over the counter.

Condition or disease Intervention/treatment Phase
Prostate Cancer Dietary Supplement: BroccoMax® Other: Placebo Not Applicable

Detailed Description:

Eligible subjects will be randomly assigned to either BroccoMax® or placebo arm with a 1:1 randomization. Each subject will be given BroccoMax® equivalent to 4 weeks supply. Following randomization, subjects will begin to take four study tablets (BroccoMax® or placebo) in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.

Baseline evaluation will be 28 days before scheduled prostatectomy, the same day of study drug dispensation, and will include.

  1. Data collection on patient's medical history (which includes age, cancer history, review of medications, food intolerances and food habits), and concomitant medications.
  2. Physical exam including height and weight measurements.
  3. Blood (approximately 15 mL) will be collected in Serum Separator Tube-tiger tubes (SST)for determination of SFN and its metabolite levels and for biomarker analyses.
  4. Spot urine collection (15 mL) for measuring SFN and its metabolite levels.
  5. Four-week supply of study drug (BroccoMax® or Placebo) dispensation

Day 28 ± 3 days (End of study evaluation)

  1. Physical exam including height and weight measurements
  2. Blood (approximately 15 mL) will be collected in SST-tiger tubes for determination of SFN and its metabolite levels and for biomarker analyses.
  3. Spot urine collection (15 mL) for measuring SFN and its metabolite levels.
  4. Adverse event assessment.
  5. A portion of the prostate tumor after surgical resection will be fresh frozen in liquid nitrogen.
  6. After pathological assessment is complete, tumor blocks or slides (6 or more) will be requested by the clinical research coordinator from the Health Sciences Tissue Bank of the University of Pittsburgh for biomarker analyses.

Post-Treatment Follow-Up All study participants will have routine follow-up as determined by their treating urologist and/ or medical oncologist. This usually occurs 6 ± 2 weeks post-surgery and every 3 months thereafter. These are considered standard of care visits. The patient chart will be reviewed for their history and physical findings at these visits.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind randomized placebo controlled design
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer
Actual Study Start Date : May 1, 2019
Estimated Primary Completion Date : June 15, 2023
Estimated Study Completion Date : January 15, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: BroccoMax®
Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
Dietary Supplement: BroccoMax®
Nutraceutical neoadjuvant

Placebo Comparator: Placebo
Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
Other: Placebo
control
Other Name: Microcrystalline cellulose




Primary Outcome Measures :
  1. Palmitic Acid Reduction [ Time Frame: 4 weeks ]
    Change in serum levels of palmitic acid (the primary free fatty acid) in subjects treated with BroccoMax® compared to placebo.


Secondary Outcome Measures :
  1. Evaluation of safety of BroccoMax® (side effects or adverse events) [ Time Frame: 2 months ]
    Assessing any side effects or adverse events that could be associated with the oral intake of BroccoMax®

  2. Serum SFN levels [ Time Frame: 4 weeks ]
    Compare the levels of SFN and its metabolites in serum at day 14 and week 4 to baseline

  3. Urine SFN levels [ Time Frame: 4 weeks ]
    Compare the levels of SFN and its metabolites in urine at day 14 and week 4 to baseline.

  4. Prostate adenocarcinoma SFN level [ Time Frame: Week 4 ]
    Evaluate the SFN and its metabolites in the prostate/ prostate adenocarcinoma tissue.

  5. Mean proliferative index (Ki-67) and apoptotic marker (TUNEL) in prostate adenocarcinoma sections [ Time Frame: Week 4 ]
    Evaluate the biomarkers of the collected tissue.

  6. Evaluation of Prostate adenocarcinoma tissue by immunohistochemistry. [ Time Frame: Week 4 ]
    Prostate adenocarcinoma expression of acetyl-Coenzyme A carboxylase 1 (ACC1), fatty acid synthase (FASN), carnitine palmitoyltransferase1A (CPT1A), androgen receptor (AR), phosphatase and tensin homolog (PTEN), sterol regulatory binding protein 1 (SREBP-1) and c-Myc by immunohistochemistry (IHC)

  7. Evaluation of serum levels of fatty acid metabolism intermediates. [ Time Frame: Weeks 2 and 4. ]
    Evaluate Serum levels of Acetyl-Coenzyme A, Malonyl-Coenzyme A, total phospholipids, adenosine triphosphate (ATP), and global lipidemic

  8. Evaluation of prostate adenocarcinoma levels of fatty acid metabolism intermediates [ Time Frame: Week 4 ]
    Evaluate prostate adenocarcinoma levels of Acetyl-Coenzyme A, Malonyl-Coenzyme A, total phospholipids, ATP, and global lipidemic



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men ≥ 18 years of age scheduled to undergo radical prostatectomy as standard of care for a diagnosis of prostate adenocarcinoma.
  2. Subjects willing to take oral placebo or BroccoMax® pills (4 capsules twice daily after breakfast and dinner) on a daily basis for 4 weeks prior to prostatectomy. Subjects have the ability to swallow BroccoMax® or placebo pills.
  3. Subjects in good health per investigator evaluation with liver enzyme and blood count values within the following ranges:

    White blood cells ≥ 3,000/mL Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN) Aspartate Aminotransferase (AST (SGOT))/ Alanine Aminotransferase (ALT (SGPT)) ≤ 2.5 x ULN Blood Urea Nitrogen (BUN) and serum creatinine ≤ 1.5 x ULN

  4. Subjects willing to abstain from dietary sources of glucosinolates and isothiocyanates (see Appendix) for the duration of the study (4 weeks)
  5. Subjects must be fully informed of the investigational nature of this study and must sign a written informed consent in accordance within institutional and regulatory guidelines

Exclusion Criteria:

  1. Subjects ineligible to undergo prostatectomy due to co-morbidities.
  2. Subjects with a second malignancy or any other cancer at least 3 years following definitive treatment with no evidence of disease, except for adequately treated basal cell or squamous cell skin cancer.
  3. Subjects with malabsorption issues or gastrointestinal ailments than can interfere with the ability to adequately absorb SFN.
  4. Subjects with prior or concurrent androgen deprivation therapy with Luteinizing hormone-releasing hormone (LHRH) agonist or antagonists
  5. Subjects taking any other investigational agent, dietary supplement or herbal supplement or participating in clinical studies involving investigational agents
  6. Subjects with clinically significant comorbid diseases including active infection, uncontrolled angina, New York Heart Assoc. (NYHA) class III or IV heart failure, uncontrolled or uncontrollable hypertension, severe diabetes with complications, chronic liver disease.
  7. Subjects with prior history of known intolerance or allergic reactions attributed to cruciferous vegetables or specific fillers used in the placebo.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03665922


Contacts
Layout table for location contacts
Contact: Dawn McBride, RN 412-623-2764 mcbridedl@upmc.edu

Locations
Layout table for location information
United States, Pennsylvania
Shadyside Urology Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Dawn McBride, RN    412-623-2764    mcbridedl@upmc.edu   
Sub-Investigator: Ronald Benoit, MD         
Sub-Investigator: Benjamin Davies, MD         
Sub-Investigator: Jeffery Gingrich, MD         
Sub-Investigator: Ronald Hrebinko, MD         
Principal Investigator: Bruce Jacobs, MD         
Sub-Investigator: Timothy Lyon, MD         
Sub-Investigator: Jodi Maranchie, MD         
Sub-Investigator: Jennifer Taylor, MD         
Sub-Investigator: Robert Turner, MD         
Principal Investigator: Tatum Tarin, MD         
Sponsors and Collaborators
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: Bruce Jacobs, MD University of Pittsburgh

Publications:

Layout table for additonal information
Responsible Party: Bruce Jacobs, Univ of P. Physicians Faculty, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03665922     History of Changes
Other Study ID Numbers: PRO18040423
First Posted: September 11, 2018    Key Record Dates
Last Update Posted: May 24, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Bruce Jacobs, University of Pittsburgh:
prostatectomy

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Sulforafan
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents